ABBOTT LABORATORIES (ABT) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-04-29

Key Insights

Executive Vice President Mary K. Moreland acquired 5,314 ABT shares at $94.41 on 04/28/2026 through a Profit Sharing Trust, indicating insider confidence in the company's valuation at this price level.
Moreland disposed of 104,291 shares, a significantly larger transaction than the acquisition, suggesting either portfolio rebalancing, tax-loss harvesting, or liquidity needs rather than a bullish signal.
Post-transaction beneficial ownership stands at 17,159 shares held indirectly through the Profit Sharing Trust, representing a net reduction in direct insider stakes despite the recent acquisition activity.

Want the newest filings?

This analysis covers the filing from 2026-04-29. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-04-27

Philip P. Boudreau, EVP and CFO of Abbott Laboratories, acquired 8,909 shares on 04/23/2026 at $92.04 per share through a Profit Sharing Trust, indicating insider confidence in the company at current valuations.
The CFO also purchased 2,200 shares on the same date at $91.50 per share for his spouse, demonstrating a meaningful personal investment commitment alongside his executive position.
Total beneficially owned shares reached 71,172 directly, plus 9,276 indirectly through the trust, representing substantial personal stake in the company's performance and strategic direction.
The transaction occurred via Rule 10b5-1 trading plan arrangement, suggesting these purchases were pre-planned as part of a structured investment strategy rather than opportunistic trading.

Filed: 2026-03-25

The reporting person, Jacob A. Orville, a Senior Vice President at Abbott Laboratories, has acquired 13,255 common shares of the company. This suggests continued confidence and alignment of the executive team with long-term shareholder value.
The shares were acquired through a restricted stock award under the company's 2017 Incentive Stock Program, with a 2-year vesting period. This type of compensation structure incentivizes the executive to focus on the company's long-term performance.
The transaction does not involve any derivative securities, indicating a straightforward acquisition of the company's common stock by the reporting person.

Filed: 2026-02-06

The reporting person, Daniel J. Starks, a director at Abbott Laboratories (ABT), acquired a total of 10,000 common shares of the company on February 4, 2026 at weighted average prices of $109.14 and $108.33 per share.
The reporting person also holds an indirect beneficial ownership of 258 common shares of ABT through the Alynne Starks 2012 Irrevocable Trust, of which he is the sole trustee.
The insider buying activity indicates that the director is confident in the company's future prospects and aligns with the interests of shareholders.

Filed: 2026-01-26

The reporting person, Robert B. Ford, who is the Chairman and CEO of Abbott Laboratories, acquired 18,800 common shares of the company at an average price of $107.1259 per share.
The shares were acquired through direct ownership and the Ford Family Trust, which the reporting person co-manages. This suggests that the CEO has confidence in the company's future performance and is willing to invest personal funds.
The reported transaction represents a relatively small increase in the reporting person's beneficial ownership, which already stood at over 469,000 shares prior to the transaction.

Other reports for ABBOTT LABORATORIES

Quarterly Report Current Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.